A US-based and focused cannabis operator has completed a deal to buy a licensed producer (LP) in Canada, marking its official entry into the Canadian space.

MPX Bioceutical (CSE:MPX, OTC:MPXEF) announced on Monday (June 11) it had reached an agreement for the acquisition of all issued and outstanding shares of Canveda, a company that obtained its cultivation license last year.


Canveda’s LP asset is a 12,000 square foot facility in Peterborough, Ontario currently projected to produce 1,000-1,200 kilograms of cannabis flower per year.

US Election 2020 and Cannabis

 
Investing in cannabis? Read what experts have to say about cannabis and the US Election!
 

Details of the transaction

According to its statement, MPX will pay roughly C$18.1 million in a combination of C$3.1 million in cash, C$15 million worth of common shares issued at C$0.70 and 6 million common share purchase warrants.

“With the acquisition of Canveda, MPX has established a foothold in Canada to develop a vertically integrated business from seed to sale,” Michael Arnkvarn, executive vice president and chief marketing officer said in the statement.

During a conference call to update analysts and investors on the acquisition and general developments of the company, MPX also revealed it had reached US$5 million in revenue in March for its presence in Arizona and Nevada.

In the past, MPX has been clear with its intentions in the Canadian market by owning an Ontario facility in the application stage to become an LP. That process then stagnated which caused the company to direct its attention into the US market.

Now with the Canveda acquisition, MPX CEO Scott Boyes said it should help accelerate the process to obtain cultivation, sale and dealer licenses for the Owen Sound, Ontario facility.

On the same call, Boyes was asked how much money does the company plan to spend in Canada now with this acquisition and if Canveda affects the development plans for the facility in Owen Sound.

Boyes said the company still plans to spend between C$3 and C$4 million for the development of the non-LP asset in Ontario and has shifted its cultivation capacity strategy since the company believes current LPs already have sufficient capacity for the Canadian market. Boyes said:

We think there’s going to be some downward pressure on flower and trim pricing and the only place to hold a reasonable margin is in the producing of distillates and secondary products so we no longer plan massive cultivation development in Owen Sound, we will focus on some high-end cultivation, cultivation that we can use for our own concentrate production and will focus on producing concentrates and other products.

Market reaction to LP acquisition by MPX

MPX’s share price has been trending upward since the purchase of Canveda. On Monday the company closed the trading session with a share price of C$0.92 thanks to a 4.55 percent increase.

After the Tuesday (June 12) session ended, MPX’s shares had elevated 2.17 percent and reached a price of C$0.94.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

  • Q3 Systemwide Pro Forma Revenue increased 18% quarter-over-quarter to $22.3 million , 170% year-over-year – Company became cash flow positive from operations in August
  • Company sale leaseback transaction with Innovative Industrial Properties scheduled to close within two weeks. As a result of close, together with proceeds from the recently closed bought deal financing, the Company will have $16 million of cash and $43 million in long-term debt
  • Company is in the process of acquiring acreage to construct up to 210,000 square feet of flowering canopy and supporting manufacturing facility in Cook County, Illinois to exponentially increase capacity in state
  • Initial guidance for 2021 with Systemwide Pro Forma Revenue of $170 -180 million and Adjusted EBITDA of $40 -50 million
  • The Company’s existing projects at maturity represent a long-term revenue and EBITDA opportunity upwards of $650 million and $250 million

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) today announced its financial results for the third quarter of 2020. All financial information is presented in U.S. dollars unless otherwise indicated.

Third Quarter 2020 Financial Results Highlights

Keep reading... Show less
  • Q3 Systemwide Pro Forma Revenue increased 18% quarter-over-quarter to $22.3 million , 170% year-over-year – Company became cash flow positive from operations in August
  • Company sale leaseback transaction with Innovative Industrial Properties scheduled to close within two weeks. As a result of close, together with proceeds from the recently closed bought deal financing, the Company will have $16 million of cash and $43 million in long-term debt
  • Company is in the process of acquiring acreage to construct up to 210,000 square feet of flowering canopy and supporting manufacturing facility in Cook County, Illinois to exponentially increase capacity in state
  • Initial guidance for 2021 with Systemwide Pro Forma Revenue of $170 -180 million and Adjusted EBITDA of $40 -50 million
  • The Company’s existing projects at maturity represent a long-term revenue and EBITDA opportunity upwards of $650 million and $250 million

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) today announced its financial results for the third quarter of 2020. All financial information is presented in U.S. dollars unless otherwise indicated.

Third Quarter 2020 Financial Results Highlights

Keep reading... Show less

Shareholders with losses exceeding $50,000 are encouraged to contact the firm

The Law Offices of Frank R. Cruz reminds investors of the upcoming December 1, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Aurora Cannabis, Inc. (“Aurora” or the “Company”) (NYSE: ACB ) securities between February 13, 2020 and September 4, 2020 , inclusive (the “Class Period”).

Keep reading... Show less

Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce the launch of preclinical research studies using psilocybin and N-Acetylcysteine (“NAC”) for the treatment of mild traumatic brain injuryconcussion (“mTBI”) with post-traumatic stress disorder (“PTSD”). The study is in collaboration with a multidisciplinary team of scientists and physicians at the University of Miami Miller School of Medicine under the lead of Michael E. Hoffer, M.D., professor of otolaryngology and neurological surgery.

NAC has been shown to be safe and efficacious in a phase I human clinical study in treating military personnel who had suffered mTBI. The initial research focus is to demonstrate the safety and efficacy of the combination of psilocybin and NAC using broadly accepted rodent models. Final results are expected in 2021. Once this is established, more specific work can examine dose response, medicine uptake, and medicine levels. The research team at the Miller School of Medicine has conducted prior studies involving NAC with mTBI and has a license from the United States Drug Enforcement Administration to conduct research using Schedule I controlled substances, which includes psilocybin.

Keep reading... Show less

Aphria Inc. (” Aphria “, ” we ” or the ” Company “) (TSX: APHA) (NASDAQ: APHA), a leading global cannabis company inspiring and empowering the worldwide community to live their very best life, announced it has closed the accretive, strategic acquisition (the ” Acquisition “) of  SW Brewing Company, LLC (” SweetWater Brewing Company ” or ” SweetWater “), one of the largest independent craft brewers in the United States (“U.S.”) based on volume. Beginning with the flagship 420 beverage offerings, SweetWater has created an award-winning lineup of year-round, seasonal and specialty beers, a portfolio of brands closely aligned with a cannabis lifestyle.

Keep reading... Show less